Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03161574 | FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer | withdrawn | Phase 2 | 0 | Guangxi Medical UniversityOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00387530 | Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Aug 2, 2019 | clinicaltrials |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT03794596 | A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer(IMpALA) | withdrawn | Phase 2 | 0 | The Christie NHS Foundation TrustOTHER | 0 | Jul 22, 2019 | clinicaltrials |
| NCT03778879 | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B | withdrawn | Phase 1 / Phase 2 | 0 | Alan KatzOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03393273 | Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft(IFM2016-03) | withdrawn | Phase 2 | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | withdrawn | Phase 1 / Phase 2 | 0 | William Grosh, MDOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT03836157 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | withdrawn | Phase 2 | 0 | University of OklahomaOTHER | 1 | Jun 27, 2019 | clinicaltrials |
| NCT00960544 | Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 14, 2019 | clinicaltrials |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Hitendra PatelOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT02527772 | Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma(LD-FOX4/HCC) | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02534337 | Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02584556 | Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02585479 | Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT03919383 | Phase II of Lenvatinib Plus Toripalimab for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT03797443 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Piedmont Cancer InstituteOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT03432676 | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 30, 2019 | clinicaltrials |
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Medical College of WisconsinOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT03121417 | Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT03392571 | Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients | withdrawn | Phase 2 | 0 | Pancreatic Cancer Research TeamOTHER | 0 | May 7, 2019 | clinicaltrials |
| NCT03775707 | Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria | withdrawn | Phase 2 | 0 | Shi MingOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03780634 | HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03803254 | HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03782831 | TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT03644589 | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Apr 26, 2019 | clinicaltrials |
| NCT03058939 | Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT03325465 | Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT03746249 | Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03419559 | Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00829647 | A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Scripps HealthOTHER | 0 | Apr 11, 2019 | clinicaltrials |
| NCT03114280 | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)(PICH) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Antoine LacassagneOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT02542930 | Abscopal Effect for Metastatic Non-small Cell Lung Cancer. | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 0 | Mar 26, 2019 | clinicaltrials |
| NCT03856112 | Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Mar 26, 2019 | clinicaltrials |
| NCT03221634 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) | withdrawn | Phase 2 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Mar 25, 2019 | clinicaltrials |
| NCT02542137 | Abscopal Effect for Metastatic Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 0 | Mar 21, 2019 | clinicaltrials |
| NCT02948101 | PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT02355431 | Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations | withdrawn | Phase 2 | 0 | Incyte CorporationINDUSTRY | 1 | Mar 8, 2019 | clinicaltrials |
| NCT03187691 | Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia | withdrawn | Phase 2 | 0 | Matinas BioPharma Nanotechnologies, Inc.INDUSTRY | 0 | Mar 8, 2019 | clinicaltrials |
| NCT03699384 | Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT03346304 | Photodynamic Therapy for the Prevention of Lung Cancer(PEARL) | withdrawn | Phase 2 / Phase 3 | 0 | University College, LondonOTHER | 0 | Feb 1, 2019 | clinicaltrials |
| NCT03147196 | Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 22, 2019 | clinicaltrials |
| NCT00547443 | Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT03323710 | Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Military Institute od Medicine National Research InstituteOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT01479582 | Providing Access to Cord Blood Units for Transplants | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 21, 2018 | clinicaltrials |
| NCT03234842 | Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer(ES01) | withdrawn | Phase 2 | 0 | University of FloridaOTHER | 1 | Dec 21, 2018 | clinicaltrials |
| NCT03419130 | Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT00257829 | Improving Tumor Oxygenation in Cervical Cancer | withdrawn | Phase 2 | 0 | University of California, IrvineOTHER | 0 | Dec 3, 2018 | clinicaltrials |
| NCT00621036 | Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 26, 2018 | clinicaltrials |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Nov 21, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Aug 8, 2019source: clinicaltrials